Alterity Therapeutics Expands Leadership Amid Promising Advances in Neurodegenerative Treatment
The Shift in Leadership Strategy
In a significant move on November 18, 2024, Alterity Therapeutics appointed Abby Macnish Niven as its Company Secretary, a role she assumes in tandem with her recent appointment as Chief Financial Officer. This dual role comes during a pivotal time for the Melbourne-based biopharmaceutical company, which is gaining attention for its innovative approach to combating neurodegenerative diseases. Previously held by Phillip Hains, the Company Secretary position will now be instrumental in steering Alterity s strategic initiatives as it develops therapies targeting complex conditions, particularly Multiple System Atrophy (MSA).
Turning Clinical Promises into Therapeutic Reality
Concurrent with this leadership adjustment, Alterity Therapeutics has made
Comments